Lexaria (LXRP) Receives Notice of Allowance for Bioavailability Patent
Ryan Allway
July 12th, 2016
News, Top News
[stockchart symbol=LXRP]
Lexaria Corp. [stockquote symbol=LXRP], a food sciences company focused on the delivery of active compounds that can behave as superfoods through its proprietary infusion technologies, recently announced that it has received its first Notice of Allowance for one of its U.S. patent applications from the U.S. Patent and Trademark Office (USPTO).
According to the company’s press release:
Lexaria Bioscience Corp. (LXRP) (CSE:LXX) (the “Company”) is very pleased to announce a watershed event in its advancement as a bioscience company: it has just received its first Notice of Allowance for one of its US patent applications from the US Patent and Trademark Office (USPTO).
Lexaria is very pleased at the unexpectedly rapid allowance of these first claims protecting its intellectual property portfolio by the USPTO, and has every reason to believe this is only the first of what will be several successful patent applications. The Notice of Allowance concludes the substantive examination of US Patent Application Serial No. 14/735,844 by the USPTO and will result in the issuance of a US patent after remaining administrative processes are completed in the next several weeks. The US patent scheduled to issue from this application will expire no earlier than June 10, 2035.
This patent application allowance adds value to the Company in three crucial ways:
First, the issued patent will provide us with the exclusive right to prevent others from making, using, selling, or importing the claimed invention in the US, and the right to collect damages for any such unlawful activity. This greatly strengthens our competitive position and elevates the relative value of our intellectual property (IP).
Second, it strengthens the Company’s financial leverage for existing and future technology licensing agreement negotiations with our USPTO-recognized IP. Lexaria previously began monetizing its IP in May 2016 with our first licensing agreement, and is now in a stronger position than ever to both continue and even accelerate this process.
Third, it strengthens our optimism that the Company will achieve similar success with additional IP claims it has filed with the USPTO and under the international Patent Cooperation Treaty (PCT). As Lexaria continues to expand its allowable and issued patent portfolio, its ability to enter additional technology licensing agreements should greatly expand.
The title of the patent application allowed by the USPTO is “Food and Beverage Compositions Infused with Lipophilic Active Agents and Method of Use Thereof.” The allowed application includes a series of Lexaria’s method claims for combining a lipophilic active agent together with a bioavailability and taste enhancing oil by way of dehydration or lyophilization, and doing so in contact with a food product substrate material. Lexaria still has a number of additional patent applications undergoing review by the USPTO and patent application continuations planned in order to further broaden its expected set of compositional and method patent claims regarding the technology. As a result, it is not possible to know how many additional allowed patents may be achievable although there could be many.
“Lexaria believes that anytime and every time it is successful in progressing a patent application into a granted patent, it not only reinforces the validity of its underlying encapsulation technology, but it also opens new areas of potential revenue generation and economic activity,” said John Docherty, President of the Company. “Lexaria’s allowed and pending patent portfolio is both broad and deep and its executives continue to investigate additional new areas of IP that could be symbiotic with that which is already known.”
Lexaria’s business plan is focused in part on the leveraging of its IP prowess in disparate areas of the economy, such as the rapidly evolving cannabinoid sector; the vitamin sector; the NSAID sector; and even the nicotine sector. Lexaria’s unique technology allows for more efficient and effective absorption of molecules such as these, while simultaneously masking, and at times even eliminating, inherent strong flavours and/or odors typical of those molecules. Lexaria’s technology is extremely cost effective to implement and applicable to the widest imaginable spectrum of foods including, but not limited to chocolates, candies, coffee, tea, a wide variety of other beverages, protein bars, cookies, pastas, entrees, breads, and much more.
The Company is grateful for the dedication and vision of its technology founders, of its talented IP team, and of its management team who have together guided this successful process.
About Lexaria
Lexaria Bioscience Corp. is a food sciences company focused on the delivery of active compounds that can behave as superfoods through its proprietary infusion technologies. Lexaria’s technology enables higher bioavailability rates for CBD; THC; NSAIDs; Nicotine and other molecules than is possible without lipophilic enhancement technology. This can allow for lower overall dosing requirements and/or higher effectiveness in active molecule delivery. Lexaria hopes to reduce other common but less healthy ingestion methods such as smoking as it embraces the benefits of public health. www.lexariaenergy.com.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
SinglePoint, Inc (SING) is a technology and investment company with a focus on acquiring companies that will benefit from the injection of growth capital and technology integration.
Wildflower Brands is a Vancouver-based company developing and designing brands that focus on plant-based health and wellness products.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
